GLP-1 Side Effects: A Plain-English Guide to What the Trials Actually Showed

Most plain-English coverage of GLP-1 side effects either understates the gut issues most patients actually experience or overstates the rare risks (pancreatitis, thyroid cancer) that almost never occur in practice. This article does neither. We pulled the actual adverse-event tables from the STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) Phase 3 trials, plus the 2025 FDA-approved prescribing labels for Wegovy and Zepbound, and walk through each side effect category with verified percentages. Every percentage is cited to its source PMID. Bonus: a counterintuitive finding the lay press has missed.

The dominant signal: GI side effects from semaglutide (STEP-1)

STEP-1 randomized 1,961 adults with BMI ≥ 30 (or ≥ 27 with weight comorbidities) to weekly semaglutide 2.4 mg or placebo for 68 weeks [1]. The published adverse-event table is unambiguous about where the safety burden actually sits: in the gut.

Read across the rows: nearly half of patients on semaglutide experienced nausea at some point during the trial. Roughly a quarter experienced vomiting. These aren't fringe outcomes — they're what most patients should expect. The good news is that only 4.5% of trial participants discontinued treatment because of side effects, which means the vast majority of the GI symptoms were mild-to-moderate and resolved with continued use, especially as the dose escalation phase ended [1].

SURMOUNT-1: tirzepatide adverse events at three doses

SURMOUNT-1 randomized 2,539 adults to weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks [2]. The trial reported adverse events separately for each dose tier, which lets us see the dose-response curve directly:

The counterintuitive finding: semaglutide had higher nausea than tirzepatide

Cross-comparing the two tables produces a result that contradicts the conventional lay-press assumption that “tirzepatide is harder on the gut.”

At their maximum doses, semaglutide 2.4 mg had 43.9% nausea and 24.5% vomiting [1], while tirzepatide 15 mg had 31.0% nausea and 12.2% vomiting [2]. Semaglutide's GI burden is materially higher — particularly for vomiting, where the absolute risk difference vs placebo is more than double tirzepatide's.

Two important caveats before drawing strong conclusions from this:

1. No head-to-head trial. STEP-1 and SURMOUNT-1 recruited different populations, ran for different durations (68 vs 72 weeks), and used different dose escalation schedules. Comparing across trials is suggestive, not conclusive.
2. STEP-1 used a faster escalation. Semaglutide STEP-1 escalated from 0.25 mg to 2.4 mg over 16 weeks (a relatively rapid 4-week increment ladder), while SURMOUNT-1 tirzepatide used a 4-week increment from 2.5 mg up. Faster escalation correlates with higher GI symptom burden in both drug classes — so part of the gap may be protocol-driven, not drug-driven.

That said, the practical takeaway for patients is that tirzepatide is not obviously worse for the gut than semaglutide, and may actually be modestly better-tolerated at maximum dose. For patients sensitive to nausea, the dose escalation schedule matters more than the choice between the two drugs.

Pancreatitis: a real warning, but not a real signal

Both Wegovy and Zepbound carry FDA labeling that lists acute pancreatitis as a possible adverse reaction. The Wegovy label states: “Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY.” Patients are instructed to discontinue if pancreatitis is suspected.

The actual numerical risk in clinical trials is much smaller than the warning language implies. In SURMOUNT-1, four adjudication-confirmed pancreatitis cases were distributed across treatment groups including placebo, with none adjudicated as severe [2]. A 2023 systematic review and meta-analysis of 9 randomized controlled trials including 6,828 tirzepatide recipients found that an increased risk of pancreatitis was NOT statistically associated with tirzepatide (RR 1.46, 95% CI 0.59–3.61, p = 0.436) [5]. The relative risk point estimate is elevated but the confidence interval crosses 1.0, which means the trial-level evidence cannot rule out either a small real effect or no effect at all.

Translation: the FDA pancreatitis warning is a regulatory precaution based on the GLP-1 mechanism (these drugs do increase pancreatic enzyme exposure) and a small number of post-marketing case reports. The randomized trial data does not show a statistically meaningful elevation. The practical risk for any individual patient is real but very small, and prescribers appropriately screen for prior pancreatitis history before starting therapy.

Gallbladder events: a smaller signal that IS statistically real

Gallbladder disease is a different story. The Zepbound label reports cholelithiasis (gallstones) in 1.1% of tirzepatide recipients vs 1.0% of placebo and cholecystitis (gallbladder inflammation) in 0.7% vs 0.2% [6]. The 2023 meta-analysis confirmed that the composite of gallbladder or biliary disease WAS significantly associated with tirzepatide compared with placebo or basal insulin [5].

The FDA label notes the proximate cause: “Acute gallbladder events were associated with weight reduction” [6]. In other words, the gallbladder signal is most likely a consequence of rapid weight loss in general (any major weight loss, regardless of mechanism, increases gallstone risk because of cholesterol mobilization from fat stores), not a drug-specific toxicity. This is consistent with the same pattern seen after bariatric surgery, very-low-calorie diets, and other rapid-weight-loss interventions.

Thyroid C-cell tumor warning: rodent-only evidence

Both Wegovy and Zepbound carry a black-box warning about medullary thyroid carcinoma (MTC). The warning is based on rodent studies showing dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant plasma exposures [6]. The Zepbound label is explicit: “It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide- induced rodent thyroid C-cell tumors has not been determined” [6].

No human MTC cases have been reported in the published Phase 3 obesity trials for either semaglutide or tirzepatide. Both drugs are contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which is the appropriate precaution given the rodent signal.

Practically: if you don't have a personal or family history of thyroid cancer, the rodent thyroid signal is not a meaningful clinical concern. If you do, both drugs are off the table.

Hypoglycemia: low risk, with one important exception

GLP-1 receptor agonists are glucose-dependent insulin secretagogues — they only stimulate insulin release when blood glucose is elevated, which provides built-in protection against hypoglycemia in monotherapy. STEP-1 reported hypoglycemia in just 0.6% of semaglutide-treated participants, comparable to the placebo rate [1].

The exception is patients who take semaglutide or tirzepatide alongside insulin or sulfonylureas. Combination therapy dramatically increases hypoglycemia risk (16–30% across various trials), which is why prescribers typically lower insulin or sulfonylurea doses when initiating a GLP-1.

Injection site reactions

Injection site reactions were reported in 1.9% to 4.5% of tirzepatide recipients across Phase 3 trials [2]. Most were mild to moderate (transient redness, itching, or small bruise at the injection site) and did not lead to treatment discontinuation. Injection technique matters — rotating injection sites, allowing the injectable to reach room temperature before use, and using a fresh needle each time all reduce the rate.

“Ozempic face”: not actually a documented adverse event

The widely-reported “Ozempic face” phenomenon — facial volume loss, skin laxity, and accelerated facial aging in people on GLP-1 therapy — is real, but it's not a documented adverse event in any Phase 3 trial. It's a cosmetic consequence of rapid weight loss, not a drug-specific toxicity. Approximately 20– 50% of weight lost on GLP-1 therapy comes from lean mass, including facial subcutaneous fat — see our investigation of semaglutide and lean mass loss for the trial-data background on the body composition question.

The phenomenon affects every drug that produces dramatic weight loss, including bariatric surgery, very-low-calorie diets, and other GLP-1 / GIP/GLP-1 agonists (dulaglutide, liraglutide, tirzepatide). It's not unique to semaglutide despite the nickname. The clinical literature characterizes it as a real cosmetic outcome of rapid lean-mass loss, not as a safety signal. For people concerned about it, the published mitigation strategies are slower dose escalation (slower weight loss trajectory), increased dietary protein, and resistance training to preserve lean mass.

Bottom line: how to think about GLP-1 safety

1. The dominant safety burden is GI symptoms during dose escalation. 40–73% of patients experience nausea, diarrhea, or vomiting at some point. Most are mild-to-moderate and resolve. About 4–7% of patients discontinue because of side effects.
2. Pancreatitis warning is regulatory, not statistical. The randomized trials do not show a significant pancreatitis signal beyond placebo. The warning exists because the mechanism is plausible and post-marketing case reports accumulate at the population level.
3. Gallbladder signal is real but small, and is mostly a consequence of rapid weight loss. 0.7% cholecystitis on tirzepatide vs 0.2% on placebo.
4. Thyroid warning is rodent-only. No human MTC signal in Phase 3 trials. Contraindicated only in patients with personal or family history of MTC or MEN 2.
5. Hypoglycemia risk is essentially zero in monotherapy and substantial when combined with insulin or sulfonylurea.
6. “Ozempic face” is real but not a drug adverse event. It's lean-mass loss from rapid weight reduction, common to every effective weight loss intervention.

For most patients without specific contraindications, the safety ceiling on GLP-1 weight loss therapy is GI tolerance during dose escalation. The serious-but-rare risks (pancreatitis, MTC) are either statistically insignificant in the trial data or based on non-human evidence. The cosmetic concerns (facial volume, sarcopenia) are functions of rapid weight loss in general and can be mitigated by slower dose escalation and dietary protein.

For our editorial coverage of how to choose between providers offering compounded versions of these drugs, see the semaglutide provider rankings and the tirzepatide provider rankings. For the head-to-head efficacy comparison between the two drugs beyond just side effects, see our tirzepatide vs semaglutide head-to-head deep dive.